* Sutro Biopharma Inc is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
* The South San Francisco California-based company is expected to report a 9.9% decrease in revenue to $15.253 million from $16.92 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sutro Biopharma Inc is for a loss of 73 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Sutro Biopharma Inc is 11.50, above its last closing price of $4.16.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.76 -0.79 -0.59 Beat 25.5
Jan. 1 2024 -0.88 -0.92 -0.95 Missed -3
Dec. 31 2023 -0.82 0.52 Beat 163.2
Sep. 30 2023 -0.74 -0.74 -0.81 Missed -10.1
Jan. -0.75 -0.73 -0.64 Beat 12.6
1 0001
Jan. 1 0001 -0.80 -0.81 -0.85 Missed -4.8
Dec. 31 2022 -0.61 -0.62 -0.68 Missed -9.5
Sep. 30 2022 -0.75 -0.74 -0.37 Beat 49.9
This summary was machine generated November 8 at 15:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments